Jamie B. Oughton

Assessment of ibrutinib plus rituximab in front-line CLL (FLAIR trial): study protocol for a phase III randomised controlled trial

Laura Collett, Dena Howard, Talha Munir et al. · Trials · 2017 · 34 citations · Full text

Medicine, Immunology, Pharmacotherapy +16

CONCORDE: A phase I platform study of novel agents in combination with conventional radiotherapy in non-small-cell lung cancer

Gerard Walls, Jamie B. Oughton, Anthony J. Chalmers et al. · Clinical and Translational Radiation Oncology · 2020 · 34 citations · Full text

Medicine, Oncology, Radiation Oncology +16

Radical cystectomy (bladder removal) against intravesical BCG immunotherapy for high-risk non-muscle invasive bladder cancer (BRAVO): a protocol for a randomised controlled feasibility study

Jamie B. Oughton, Heather Poad, Maureen Twiddy et al. · BMJ Open · 2017 · 27 citations · Full text

Medicine, Oncology, Surgery +15

NET-02: a randomised, non-comparative, phase II trial of nal-IRI/5-FU or docetaxel as second-line therapy in patients with progressive poorly differentiated extra-pulmonary neuroendocrine carcinoma

Mairéad G. McNamara, Jayne Swain, Zoe Craig et al. · EClinicalMedicine · 2023 · 21 citations · Full text

Medicine, Oncology, Pharmacotherapy +16

Lapatinib plus Capecitabine versus Trastuzumab plus Capecitabine in the Treatment of Human Epidermal Growth Factor Receptor 2-positive Metastatic Breast Cancer with Central Nervous System Metastases for Patients Currently or Previously Treated with Trastuzumab (LANTERN): a Phase II Randomised Trial

Jenny F. Seligmann, Alexandra Wright‐Hughes, A. Pottinger et al. · Clinical Oncology · 2020 · 20 citations

Medicine, Oncology, Pharmacology +17